Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The GBA1 p.E427K (p.E388K) Variant Is a Risk Factor for Synucleinopathies: A Meta-Analysis.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Correlation of spirituality with short-term outcomes after lumbar spine surgery: a prospective observational study.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·2026
Same author

Glucosylsphingosine (Lyso-Gb1) Dynamics in Untreated States in Gaucher Disease.

International journal of molecular sciences·2026
Same author

The <i>GBA1</i> p.E427K (p.E388K) Variant is a Risk Factor for Synucleinopathies: A Meta-Analysis.

medRxiv : the preprint server for health sciences·2026
Same author

Genotypes truncating the intracellular tail of human pre-TCRα: From amorphic to isomorphic.

Journal of human immunity·2026
Same author

Pathogenic or Likely Pathogenic GRN Variants Are Found in 0.1% of Parkinson's Disease Patients.

Movement disorders : official journal of the Movement Disorder Society·2025

Related Experiment Video

Updated: Jul 2, 2026

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
12:18

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles

Published on: February 1, 2020

Methylation-specific multiplex ligation-dependent probe amplification in meningiomas.

Christian Ewald1, Thomas Hofmann, Susanne A Kuhn

  • 1Klinik für Neurochirurgie, Universitätsklinikum, Jena, Germany.

Journal of Neuro-Oncology
|September 3, 2008
PubMed
Summary

Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) can detect genomic alterations in meningiomas. This method identified increased aberrations with higher tumor grades, with von Hippel-Lindau gene deletion being most common.

More Related Videos

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Related Experiment Videos

Last Updated: Jul 2, 2026

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles
12:18

LINE-1 Methylation Analysis in Mesenchymal Stem Cells Treated with Osteosarcoma-Derived Extracellular Vesicles

Published on: February 1, 2020

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Tumor suppressor genes (TSGs) are inactivated by genomic loss and promoter methylation.
  • Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) offers simultaneous detection of these alterations.

Purpose of the Study:

  • To apply MS-MLPA for detecting genomic copy number changes and promoter methylation in meningiomas.
  • To correlate genetic alterations with tumor grade and clinical features.

Main Methods:

  • MS-MLPA was performed on 15 meningiomas of varying WHO grades.
  • Two MS-MLPA probe sets were utilized to analyze 55 TSGs for copy number changes and 36 TSGs for promoter methylation.

Main Results:

  • Genomic deletion findings were consistent with previous studies.
  • The number of detected aberrations per tumor increased with higher histopathological grades.
  • Von Hippel-Lindau (VHL) gene deletion was the most frequent event (12/15 tumors) and associated with peritumoral edema.
  • Methylation was infrequent, affecting only single genes in four tumors.

Conclusions:

  • MS-MLPA is effective in identifying genomic alterations in meningiomas.
  • A meningioma-specific MS-MLPA probe set could be valuable for research and diagnostics.